Kuros Biosciences announced the first commercial uses of MagnetOs bone graft substitute in the U.S. and U.K., in spinal fusion and scoliosis procedures, respectively.
Kuros received FDA 510(k) clearance to market MagnetOs putty as an autograft extender in the posterolateral spine in 3Q17, and gained approval under the CE Mark earlier this year.
The company will increase its commercial activities in Europe and the U.S. in 2H18.
Kuros Biosciences announced the first commercial uses of MagnetOs bone graft substitute in the U.S. and U.K., in spinal fusion and scoliosis procedures, respectively. Kuros received FDA 510(k) clearance to market MagnetOs putty as an autograft extender in the posterolateral spine in 3Q17, and gained approval under the CE Mark earlier this year....
Kuros Biosciences announced the first commercial uses of MagnetOs bone graft substitute in the U.S. and U.K., in spinal fusion and scoliosis procedures, respectively.
Kuros received FDA 510(k) clearance to market MagnetOs putty as an autograft extender in the posterolateral spine in 3Q17, and gained approval under the CE Mark earlier this year.
The company will increase its commercial activities in Europe and the U.S. in 2H18.
Copy to clipboard 
